학술논문
Minimum information about a bioactive entity (MIABE)
Document Type
Report
Viewpoint essay
Viewpoint essay
Author
Orchard, Sandra; Al-Lazikani, Bissan; Bryant, Steve; Clark, Dominic; Calder, Elizabeth; Dix, Ian; Engkvist, Ola; Forster, Mark; Gaulton, Anna; Gilson, Michael; Glen, Robert; Grigorov, Martin; Hammond-Kosack, Kim; Harland, Lee; Hopkins, Andrew; Larminie, Christopher; Lynch, Nick; Mann, Romeena K.; Murray-Rust, Peter; Piparo, Elena Lo; Southan, Christopher; Steinbeck, Christoph; Wishart, David; Hermjakob, Henning; Overington, John; Thornton, Janet
Source
Nature Reviews Drug Discovery. September 2011, Vol. 10 Issue 9, p661, 9 p.
Subject
Language
English
ISSN
1474-1776
Abstract
The process of identifying and developing molecules with useful bioactive properties, such as pharmaceutical agents, pesticides and food additives, is fraught with difficulty. In the pharmaceutical industry only a very [...]
Bioactive molecules such as drugs, pesticides and food additives are produced in large numbers by many commercial and academic groups around the world. Enormous quantities of data are generated on the biological properties and quality of these molecules. Access to such data--both on licensed and commercially available compounds, and also on those that fail during development --is crucial for understanding how improved molecules could be developed. For example, computational analysis of aggregated data on molecules that are investigated in drug discovery programmes has led to a greater understanding of the properties of successful drugs. However, the information required to perform these analyses is rarely published, and when it is made available it is often missing crucial data or is in a format that is inappropriate for efficient data-mining. Here, we propose a solution: the definition of reporting guidelines for bioactive entities --the Minimum Information About a Bioactive Entity (MIABE)--which has been developed by representatives of pharmaceutical companies, data resource providers and academic groups.
Bioactive molecules such as drugs, pesticides and food additives are produced in large numbers by many commercial and academic groups around the world. Enormous quantities of data are generated on the biological properties and quality of these molecules. Access to such data--both on licensed and commercially available compounds, and also on those that fail during development --is crucial for understanding how improved molecules could be developed. For example, computational analysis of aggregated data on molecules that are investigated in drug discovery programmes has led to a greater understanding of the properties of successful drugs. However, the information required to perform these analyses is rarely published, and when it is made available it is often missing crucial data or is in a format that is inappropriate for efficient data-mining. Here, we propose a solution: the definition of reporting guidelines for bioactive entities --the Minimum Information About a Bioactive Entity (MIABE)--which has been developed by representatives of pharmaceutical companies, data resource providers and academic groups.